Shares - - TALKING POINT -


23andMe iden­ti­fies how ge­net­ics can in­flu­ence risks for cer­tain dis­eases and if you are a car­rier of in­her­ited con­di­tions such as breast can­cer and Parkin­son’s dis­ease.

This in­for­ma­tion can then be used to help car­ri­ers be aware of con­di­tions that they may pass on to chil­dren, so they can be closely mon­i­tored, or even to make changes to their own lives.

23andMe re­cently dom­i­nated head­lines af­ter re­veal­ing ex­clu­sive a four-year col­lab­o­ra­tion with phar­ma­ceu­ti­cal colos­sus Glax­oSmithK­line (GSK) for cus­tomer data to help the lat­ter dis­cover drug tar­gets.

Var­i­ous news out­lets spec­u­late the busi­ness is cur­rently worth $1.8bn. There is no news on a stock mar­ket flota­tion, but this is cer­tainly a name to keep watch­ing. (LMJ)


It may not be a house­hold name, but cy­ber­se­cu­rity firm Dark­trace is now worth $1.65bn – not bad for a five-year-old firm.

It uses ma­chine learn­ing and ar­ti­fi­cial in­tel­li­gence tools to alert cus­tomers when their sys­tems have been in­fil­trated.

Its soft­ware learns the pat­terns of nor­mal be­hav­iour in­side a com­puter net­work, so it can spot anom­alies when they oc­cur and stop prob­lems from es­ca­lat­ing into a cri­sis. The down­side for in­vestors is that it has no cur­rent plans to float on the stock mar­ket. (DC)


Dig­i­tal health busi­ness Babylon Health is aim­ing to re­duce the strain on health­care ser­vices by help­ing peo­ple in­ter­pret symp­toms via its ar­ti­fi­cial in­tel­li­gence and di­rect them to a hu­man doc­tor if med­i­cal care is needed.

The com­pany also con­nects pa­tients with doc­tors via phone calls or video chat on their mo­bile, so they can re­ceive med­i­cal ad­vice and po­ten­tially a pre­scrip­tion.

Babylon cur­rently has op­er­a­tions in the UK and Rwanda, but plans to ex­pand into China, the US, Canada and the Mid­dle East. (LMJ)

Newspapers in English

Newspapers from UK

© PressReader. All rights reserved.